Table 2.
GCA with TB | GCA without TB | P value | |||||
---|---|---|---|---|---|---|---|
Mean ± SD (range) | n (%) | Total n | Mean ± SD (range) | n (%) | Total n | ||
Laboratory findings | |||||||
ESR (mm/h) | 94.50 ± 28.21 (44−140) | 20 | 90.01 ± 27.74 (21−140) | 71 | 0.526 | ||
CRP (mg/L) | 76.71 ± 59.67 (2.47−197) | 20 | 80.68 ± 63.45 (1.8−275.66) | 71 | 0.803 | ||
ALB (g/L) | 33.20 ± 5.65 (24−47) | 20 | 32.38 ± 4.30 (22−42) | 69 | 0.486 | ||
WBC ( × 109/L) * | 6.92 ± 2.39 (1.47−10.91) | 20 | 9.80 ± 4.42 (2.36−26.60) | 69 | 0.006 | ||
Leukopenia | 3 (15) | 20 | 3 (4.3) | 69 | 0.148 | ||
LYM ( × 109/L) | 1.65 ± 0.67 (0.62−2.94) | 20 | 1.63 ± 0.78 (0.40−4.20) | 69 | 0.914 | ||
HGB (g/L) | 100.30 ± 17.14 (63−132) | 20 | 108.84 ± 19.86 (63−146) | 69 | 0.085 | ||
PLT ( × 109/L) | 400.20 ± 151.07 (130−653) | 20 | 373.75 ± 152.83 (99−725) | 69 | 0.496 | ||
Fbg (g/L) | 6.25 ± 2.69 (2.90−10.00) | 20 | 5.30 ± 2.12 (2.00−10.49) | 57 | 0.100 | ||
ANA positive | 6 (30) | 20 | 12 (17.6) | 68 | 0.229 | ||
ANCA positive | 1 (5) | 20 | 12 (18.8) | 64 | 0.138 | ||
APS positive* | 5 (55.6) | 9 | 5 (14.7) | 34 | 0.010 | ||
4 LA + 1 ACL+ | 4 ACL + 1 β 2GP1 + 1 positive for 3 antibodies | ||||||
Elevated RF | 2 (15.4) | 13 | 17 (33.3) | 51 | 0.206 | ||
Elevated IgG* | 7 (50) | 14 | 14 (23.3) | 60 | 0.046 | ||
Follow-up results | |||||||
Non-relapsing | 11 (64.7) | 17 | 26 (43.3) | 60 | 0.119 | ||
Relapsing | 2 (11.8) | 17 | 24 (40) | 60 | 0.027 | ||
Comorbid with tumors | 1 (5.9) | 17 | 1 (1.7) | 60 | 0.335 | ||
Death | 3 (17.6) | 17 | 9 (15) | 60 | 0.791 |
ALB, Albumin; ACL, anti-cardiolipin antibody; ANA, anti-nuclear antibody; ANCA, anti-neutrophil cytoplasmic antibody; APS, anti-phospholipid antibody; β 2GP1, β2glycoprotein1; CRP, C-reactive protein; ESR, erythrocyte sedition rate; Fbg, fibrinogen; GCA, giant cell arteritis HGB, hemoglobin; Ig G, immunoglobin G; LA, lupus anticoagulant; LYM, lymphocyte; PLT, platelet; RF, rheumatic factor; SD, standard deviation; TB, tuberculosis; WBC, white blood cell. *Significantly different.